Verrica Pharmaceuticals (NASDAQ:VRCA) announces positive results from an open-label Phase 2 clinical trial, COVE-1, evaluating VP-102 for the treatment of verruca vulgaris (common warts).
51% (n=18/35) of patients in Cohort 2 treated with VP-102, a 0.7% solution of cantharidin, showed complete clearance of all warts at day 84.
On the safety front, VP-102 was well-tolerated with no serious adverse events observed.
The company plans to request an end-of-Phase 2 meeting with the FDA to clarify a registration path. It plans to file a U.S. marketing application later this year for molluscum contagiosum.
Management will host a conference call tomorrow, June 27, at 8:00 am ET to discuss the results.
Shares are up 6% after hours.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.